A multicenter, randomized, double-blinded trial of pyridostigmine in postpolio syndrome

Neurology

Volumn 53, Issue 6, 1999, Pages 1225-1233

  Trojan, D A ^a   Collet, J P ^b,c   Shapiro, S ^b,c   Jubelt, B ^d   Miller, R G ^e   Agre, J C ^f   Munsat, T L ^g   Hollander, D ^g   Tandan, R ^h   Granger, C ⁱ   Robinson, A ^b   Finch, L ^a   Ducruet, T ^b   Cashman, N R ^a,j  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d State University of New York Upstate Medical University: College of Medicine   (United States)

^e CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g TUFTS UNIVERSITY   (United States)

^h UNIVERSITY OF VERMONT   (United States)

ⁱ Valeant Pharmaceuticals International   (United States)

^j UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

Insulin like growth factor I; Poliomyelitis; Pyridostigmine; Quality of life; Strength

Indexed keywords

PLACEBO; PYRIDOSTIGMINE; SOMATOMEDIN C;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART PALPITATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE FATIGUE; MUSCLE STRENGTH; POSTPOLIOMYELITIS SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEPSIS; TREATMENT OUTCOME;

EID: 0032882842     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.6.1225     Document Type: Article

References (40)

1. Jubelt B, Cashman NR. Neurological manifestations of the post-polio syndrome. CRC Crit Rev Neurobiol 1987;3:199-220.
2. Munsat TL. Post-polio syndrome. Boston: Butterworth-Heinemann, 1991.
3. Wiechers DO, Hubell SL. Late changes of the motor unit after acute poliomyelitis. Muscle Nerve 1981;4:524-528.
4. Wiechers DO. New concepts of the reinnervated motor unit revealed by vaccine-associated poliomyelitis. Muscle Nerve 1988;11:356-364.
5. Cashman NR, Maselli R, Wollman RL, Roos R, Simon R, Antel JP. Late denervation in patients with antecedent paralytic poliomyelitis. N Engl J Med 1987;317:7-12.
6. Stalberg E, Grimby G. Dynamic electromyography and muscle biopsy changes in a 4-year follow-up: study of patients with a history of polio. Muscle Nerve 1995;18:699-707.
7. McComas AJ, Quartly C, Griggs RC. Early and late losses of motor units after poliomyelitis. Brain 1997;120:1415-1421.
8. Cashman NR, Trojan DA. Correlation of electrophysiology with pathology, pathogenesis, and anti-cholinesterase therapy in post-polio syndrome. Ann NY Acad Sci 1995;753:138-150.
9. Shetty KR, Mattson DE, Rudman IW, Rudman D. Hyposomatomedinemia in men with post-poliomyelitis syndrome. J Am Geriatr Soc 1991;39:185-191.
10. Miller RG, Gelinas DF, Kent-Braun J, Dobbins T, Dao H, Dalakas M. The effect of recombinant insulin-like growth factor 1 (rhIGF-I) on exercise-induced fatigue and recovery in patients with post-polio syndrome. Neurology 1997;48:A217. Abstract.
11. Kanje M, Skottner A, Sjoberg J, Lundborg G. Insulin-like growth factor I (IGF-I) stimulates regeneration of the rat sciatic nerve. Brain Res 1989;486:396-398.
12. Caroni P, Grandes P. Nerve sprouting in innervated adult skeletal muscle induced by exposure to elevated levels of insulin-like growth factors. J Cell Biol 1990;110:1307-1317.
13. Agre JC, Rodriquez AA. Muscular function in late polio and the role of exercise in post-polio patients. Neurorehabilitation 1997;8:107-118.
14. Trojan DA, Finch L. Management of post-polio syndrome. Neurorehabilitation 1997;8:93-105.
15. Hodes R. Electromyographic study of defects of neuromuscular transmission in human poliomyelitis. Arch Neurol Psychiatry 1948;60:457-473.
16. Trojan DA, Gendron D, Cashman NR. Anticholinesterase-responsive neuromuscular junction transmission defects in post-poliomyelitis fatigue. J Neurol Sci 1993;114:170-177.
17. Trojan DA, Cashman NR. An open trial of pyridostigmine in postpoliomyelitis syndrome. Can J Neurol Sci 1995;22:223-227.
18. Seizert BP, Speier JL, Canine K. Pyridostigmine effect on strength, endurance and fatigue in post-polio patients. Arch Phys Med Rehabil 1994;75:1049. Abstract.
19. Ghigo E, Goffi S, Arvat E, et al. Pyridostigmine partially restores the GH responsiveness to GHRH in normal aging. Acta Endocrinologica (Copenh) 1990;123:169-174.
20. Muller EE, Locatelli V, Ghigo E, et al. Involvement of brain catecholamines and acetylcholine in growth hormone deficiency states. Pathophysiological, diagnostic and therapeutic implications. Drugs 1991;41:161-177.
21. Murialdo G, Fonzi S, Torre F, et al. Effects of pyridostigmine, corticotropin-releasing hormone and growth hormone-releasing hormone on the pituitary-adrenal axis and on growth hormone secretion in dementia. Neuropsychobiology 1993;28:177-183.
22. Drachman DB. The role of acetylcholine as a neurotrophic transmitter. In: Drachman DB, ed. Trophic functions of the neuron. Ann NY Acad Sci 1974;228:160-175.
23. Miller RG. The effects of nerve injury on the neuromuscular junction. In: Brumback RA, Gerst J, eds. The neuromuscular junction. Mount Kisco, NY: Futura Publishing Company, 1984:203-255.
24. Trasforini G, Margutti A, Vergnani L, et al. Evidence that enhancement of cholinergic tone increases basal plasma levels of calcitonin gene-related peptide in normal man. J Clin Endocrinol Metab 1994;78:763-766.
25. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum 1990;33:160-172.
26. Beck AT, Rush JA, Shaw BF, Emery G. Cognitive therapy of depression. New York: The Guilford Press, 1979:398-399.
27. Bourque P, Beaudette D. Etude psychometrique du questionnaire de dépression de Beck auprès d'un échantillon d'étudiants universitaires francophones. Can J Behav Sci 1982;14: 211-218.
28. Ware JE, Snow KK, Kosinski M, Gandek B. The SF-36 Health Survey: manual and interpretation guide. Boston: Nimrod Press, 1993.
29. Andres PL, Hedlund W, Finison L, Conlon T, Felmus M, Munsat TL. Quantitative motor assessment in amyotrophic lateral sclerosis. Neurology 1986;36:937-941.
30. Hare TW, Hakki AH, Lowenthal DT, Iskandrian AS, Segal BL. Simplified scale for rating perceived exertion in patients with coronary artery disease. Ann Sports Med 1985;2:64-68.
31. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Arch Neurol 1989;46:1121-1123.
32. Andres PL, Skerry LM, Munsat TL. Measurement of strength in neuromuscular disease. In: Munsat T, ed. Quantification of neurologic deficit. Boston: Butterworth, 1989:87-100.
33. National Isometric Muscle Strength (NIMS) Database Consortium. Muscular weakness assessment: use of normal isometric strength data. Arch Phys Med Rehabil 1996;77:1251-1255.
34. Finch L, Trojan D, Dannenbaum R, Venturini A, Wilford C. A treadmill walking test in post-polio syndrome patients: preliminary results. Physiotherapy Canada 1994;46(S):117. Abstract.
35. Brooks BR, Shodis KA, Lotto M, et al. Economic-, caregiver-, and ventilator-dependent stages of amyotrophic lateral sclerosis: prospective correlation with ALS Functional Rating Scale, isometric muscle strength, pulmonary function, SF-36, and Sickness Impact Profile Quality of Life Measures. Ann Neurol 1997;42:473. Abstract.
36. Kilfoil MR, St. Pierre DMM, Trojan DA, Cashman NR. The effects of pyridostigmine (Mestinon) on isokinetic evaluation of fatigue in subjects with post-poliomyelitis syndrome. Phys Ther 1992:72:S112. Abstract.
37. Maselli RA, Cashman NR, Wollman RL, Salazar-Grueso EF, Roos R. Neuromuscular transmission as a function of motor unit size in patients with prior poliomyelitis. Muscle Nerve 1992;15:648-655.
38. Dalakas MC. How to design a therapeutic study in patients with the post-polio syndrome. Ann NY Acad Sci 1995;753: 314-320.
39. Mulder DW, Rosenbaum RA, Layton DD. Late progression of poliomyelitis or forme fruste amyotrophic lateral sclerosis? Mayo Clin Proc 1972;47:756-761.
40. Halstead LS. Post-polio syndrome: Definition of an elusive concept. In: Munsat TL, ed. Post-polio syndrome. Boston: Butterworth-Heinemann, 1991:23-38.